<DOC>
	<DOCNO>NCT02400424</DOCNO>
	<brief_summary>The purpose study evaluate efficacy stereotactic lung radiation therapy concomitant radiochemotherapy unresectable stage III non-small cell lung carcinoma ( NSCLC ) peripheral primary tumor . Evaluate term local control rate 6 month addition stereotactic radiotherapy concurrent chemoradiotherapy treatment mediastinal non-resectable stage III NSCLC peripheral primary tumor . The number patient require multicenter prospective study 70 . This prospective , multicenter , non comparative non randomize study .</brief_summary>
	<brief_title>Study Efficacy SBRT Unresectable Peripheral Primary Tumor</brief_title>
	<detailed_description>Stereotactic radiotherapy SBRT ( Body Stereotactic Radiation Therapy ) allow irradiate high dose limit lesion size local control surround 80-98 % low level toxicity . We propose realize classic concomitant RT-CT mediastinal irradiation combine treatment stereotactic RT peripheral primary tumor . The estimated inclusion period approximately 3 year . Follow-up duration patient 2 year . The duration research 5 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>18 year ≤ Age ≤ 75 year PS ECOG 0 1 Histologically proven NSCLC Unresectable stage III : T1 T2 T3 ≤ 5 cm AND N2 N3 ( contralateral mediastinum homolateral supraclavicular ) . Peripheral primary tumor ≥ 1 cm ≤ 5 cm Possible concomitant chemoradiotherapy : 1 cure induction 3 concomitant cycle chemotherapy cisplatin Navelbine ® 3D conformal radiotherapy deliver 66 Gy 33 fraction mediastinal lymph node involvement without treat peripheral tumor . Adequate biological parameter Forced expiratory volume ( FEV ) ≥1 liter ≥ 30 % theoretical value Patient cover health insurance scheme Signed informed consent SCLC large cell neuroendocrine carcinoma Metastatic disease Stage IVa Pregnant breastfeed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Stereotactic lung radiation therapy</keyword>
	<keyword>Radiochemotherapy</keyword>
	<keyword>Unresectable stage III Non-Small Cell lung Carcinoma</keyword>
	<keyword>Peripheral primary tumor</keyword>
</DOC>